Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies
Jose Luis López-Campos,Laura Carrasco Hernández,Borja Ruiz-Duque,Rocio Reinoso-Arija,Candelaria Caballero-Eraso
DOI: https://doi.org/10.2147/COPD.S275943
2021-07-12
International Journal of COPD
Abstract:Jose Luis López-Campos, 1, 2 Laura Carrasco Hernández, 1, 2 Borja Ruiz-Duque, 1 Rocio Reinoso-Arija, 1 Candelaria Caballero-Eraso 1, 2 1 Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain; 2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain Correspondence: Jose Luis López-Campos Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot, s/n, Seville, 41013, Spain Tel +34 955013166 Email Recent advances in inhaled drugs and a clearer definition of the disease have made the task of managing COPD more complex. Different proposals have been put forward which combine all the available treatments and the different clinical presentations in an effort to select the best therapeutic options for each clinical context. As COPD is a chronic progressive disease, the escalation of therapy has traditionally been considered the most natural way to tackle it. However, the notion of COPD as a constantly progressing disease has recently been challenged and, in specific areas, this points to the possibility of a de-escalation in treatment. In this context, the clinician requires simple, specific recommendations to guide these changes in treatment in their daily clinical practice. To accomplish this, the first step must be a correct evaluation and an accurate initial preliminary diagnosis of the patient's condition. Thereafter, the first escalation in therapy must be introduced with caution as the disease progresses, since clinical trials are not designed with clinical decision-making in mind. During this escalation, three possibilities are open to change the current treatment for a different one within the same family, to increase non-pharmacological interventions or to increase the pharmacological therapies. Beyond that point, a patient with persistent symptoms represents a complex clinical scenario which requires a specialized approach, including the evaluation of different respiratory and non-respiratory comorbidities. Unfortunately, there are few de-escalation studies available, and these are mainly observational in nature. The debate on de-escalation in pharmacological treatment, therefore, involves two main discussion points: the withdrawal of bronchodilators and the withdrawal of inhaled steroids. Altogether, the scheme for modifying treatment must be more personalized than just adding molecules, and the therapeutic response and its conditioning factors should be evaluated at each step before proceeding further. Keywords: COPD, escalation of treatment, pharmacological therapies, precision medicine In recent decades, advances in inhaled drugs have notably expanded the therapeutic options available for treating chronic obstructive pulmonary disease (COPD). Additionally, the implementation of high-throughput technology and big data analysis have created better opportunities to describe the signs and symptoms of the disease. 1 , 2 Consequently, the task of managing COPD correctly has become more complex and there have been calls for a more simple and realistic approach. 3 Different proposals have been put forward combining all the available treatments and different clinical presentations in an effort to select the best therapeutic options for each clinical context. 4 Some proposals are based on different key variables, as in the Global Initiative for Obstructive Lung Disease (GOLD) documents. 5 Others have proposed a phenotype-based approach which has also gained popularity via the Spanish Guidelines for COPD (GesEPOC). 6 Although both initiatives have benefits and drawbacks, 7 , 8 they provide an opportunity for clinicians to manage COPD more successfully in their daily clinical practice. Nowadays, at the start of this new decade, COPD management has progressed to the stage where specific patient-based recommendations can be provided. 9 As COPD is a chronic progressive disease, escalation of therapy has been traditionally been considered the natural step in its treatment. However, the notion of COPD as a constantly progressing disease has been recently challenged, 10 , 11 and this presents the chance for de-escalation of treatment in specific scenarios. Accordingly, clear guideline -Abstract Truncated-
respiratory system